MX2023004623A - Moduladores de la via integrada de respuesta al estres. - Google Patents
Moduladores de la via integrada de respuesta al estres.Info
- Publication number
- MX2023004623A MX2023004623A MX2023004623A MX2023004623A MX2023004623A MX 2023004623 A MX2023004623 A MX 2023004623A MX 2023004623 A MX2023004623 A MX 2023004623A MX 2023004623 A MX2023004623 A MX 2023004623A MX 2023004623 A MX2023004623 A MX 2023004623A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- stress response
- modulators
- integrated stress
- response pathway
- Prior art date
Links
- 230000009221 stress response pathway Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003938 response to stress Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Amplifiers (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula (I) (ver Fórmula) (I) o sales, solvatos, hidratos, tautómeros o estereoisómeros farmacéuticamente aceptables de los mismos, en donde R1, R2, R2a, R3, R4, R4a, R4b, R4c, R4d, R4e, R5, R6 tienen el significado indicado en la descripción y en las reivindicaciones. La invención se refiere además a composiciones farmacéuticas que comprenden dichos compuestos, su uso como medicamento y en un método para tratar o prevenir una o más enfermedades o trastornos asociados con la respuesta integrada al estrés.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20203309 | 2020-10-22 | ||
| PCT/EP2021/079210 WO2022084448A1 (en) | 2020-10-22 | 2021-10-21 | Modulators of the integrated stress response pathway |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004623A true MX2023004623A (es) | 2023-05-12 |
Family
ID=73013227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004623A MX2023004623A (es) | 2020-10-22 | 2021-10-21 | Moduladores de la via integrada de respuesta al estres. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230382905A1 (es) |
| EP (1) | EP4232154A1 (es) |
| JP (1) | JP2023546225A (es) |
| KR (1) | KR20230110509A (es) |
| CN (1) | CN116964047A (es) |
| AU (1) | AU2021366303A1 (es) |
| CA (1) | CA3195293A1 (es) |
| IL (1) | IL302210A (es) |
| MX (1) | MX2023004623A (es) |
| WO (1) | WO2022084448A1 (es) |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6806562B2 (ja) | 2013-03-15 | 2021-01-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ｅＩＦ２α経路の調節因子 |
| TW201808903A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808914A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808888A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TWI763668B (zh) | 2016-05-05 | 2022-05-11 | 美商嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| EP3468960B1 (en) | 2016-06-08 | 2022-03-23 | GlaxoSmithKline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| WO2017212423A1 (en) | 2016-06-08 | 2017-12-14 | Glaxosmithkline Intellectual Property Development Limited | Chemcical compounds |
| WO2018115275A1 (en) * | 2016-12-23 | 2018-06-28 | Irbm Science Park S.P.A. | Compounds for use in the treatment of kinetoplastid infection |
| WO2018225093A1 (en) | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| WO2019008506A1 (en) | 2017-07-03 | 2019-01-10 | Glaxosmithkline Intellectual Property Development Limited | N- (3- (2- (4-CHLOROPHENOXY) ACETAMIDO) BICYCLO [1.1.1] PENTAN-1-YL) -2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES |
| EP3649108A1 (en) | 2017-07-03 | 2020-05-13 | GlaxoSmithKline Intellectual Property Development Limited | 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases |
| MX2020001352A (es) | 2017-08-09 | 2020-03-20 | Denali Therapeutics Inc | Compuestos, composiciones y metodos. |
| PL3676297T3 (pl) | 2017-09-01 | 2023-12-11 | Denali Therapeutics Inc. | Związki, kompozycje i sposoby |
| CA3080964A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| JP2021501781A (ja) | 2017-11-02 | 2021-01-21 | カリコ ライフ サイエンシーズ エルエルシー | 統合的ストレス経路の調節剤 |
| BR112020008817B8 (pt) | 2017-11-02 | 2023-10-03 | Abbvie Inc | Compostos moduladores da via de estresse integrada |
| UY37957A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| BR112020008827A2 (pt) | 2017-11-02 | 2020-10-20 | Calico Life Sciences Llc | moduladores da via de estresse integrada |
| UY37956A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| AU2018360854B2 (en) | 2017-11-02 | 2023-03-30 | Abbvie Inc. | Modulators of the integrated stress pathway |
| UY37958A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| AU2018358160B2 (en) | 2017-11-02 | 2023-03-16 | Abbvie Inc. | Modulators of the integrated stress pathway |
| CN111757739A (zh) | 2017-12-13 | 2020-10-09 | 普拉西斯生物技术有限责任公司 | 整合应激反应路径抑制剂 |
| US20210130308A1 (en) | 2018-03-23 | 2021-05-06 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| WO2019193541A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors |
| WO2019193540A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Heteroaryl derivatives of formula (i) as atf4 inhibitors |
| WO2019236710A1 (en) | 2018-06-05 | 2019-12-12 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| CA3105942A1 (en) | 2018-07-09 | 2020-01-16 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| WO2020031107A1 (en) | 2018-08-08 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| TWI771621B (zh) | 2018-10-11 | 2022-07-21 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| WO2020167994A1 (en) | 2019-02-13 | 2020-08-20 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CA3129609A1 (en) | 2019-02-13 | 2020-08-20 | Denali Therapeutics Inc. | Eukaryotic initiation factor 2b modulators |
| BR112021014514A2 (pt) | 2019-02-25 | 2021-09-28 | Praxis Biotech LLC | Inibidores de via de resposta integrada ao estresse |
| US20220177456A1 (en) | 2019-03-06 | 2022-06-09 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| US20220227747A1 (en) | 2019-04-23 | 2022-07-21 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| EP3959210A1 (en) | 2019-04-23 | 2022-03-02 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| PE20220572A1 (es) | 2019-04-30 | 2022-04-20 | Calico Life Sciences Llc | Moduladores de la via integrada del estres |
| TW202106671A (zh) | 2019-04-30 | 2021-02-16 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之調節劑 |
| CA3142748A1 (en) | 2019-06-12 | 2020-12-17 | Praxis Biotech LLC | Modulators of integrated stress response pathway |
| EP3983378A4 (en) | 2019-06-12 | 2023-12-13 | Praxis Biotech LLC | INHIBITORS OF THE INTEGRATED STRESS RESPONSE PATHWAY |
| CA3162526A1 (en) | 2020-01-28 | 2021-08-05 | Christopher John Brown | Modulators of the integrated stress response pathway |
| KR20220151635A (ko) | 2020-03-11 | 2022-11-15 | 에보텍 인터내셔널 게엠베하 | 통합 스트레스 반응 경로의 조절제 |
-
2021
- 2021-10-21 MX MX2023004623A patent/MX2023004623A/es unknown
- 2021-10-21 AU AU2021366303A patent/AU2021366303A1/en active Pending
- 2021-10-21 US US18/033,317 patent/US20230382905A1/en active Pending
- 2021-10-21 WO PCT/EP2021/079210 patent/WO2022084448A1/en active Application Filing
- 2021-10-21 EP EP21798644.7A patent/EP4232154A1/en active Pending
- 2021-10-21 KR KR1020237016360A patent/KR20230110509A/ko unknown
- 2021-10-21 CA CA3195293A patent/CA3195293A1/en active Pending
- 2021-10-21 IL IL302210A patent/IL302210A/en unknown
- 2021-10-21 CN CN202180086791.2A patent/CN116964047A/zh active Pending
- 2021-10-21 JP JP2023524307A patent/JP2023546225A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022084448A1 (en) | 2022-04-28 |
| IL302210A (en) | 2023-06-01 |
| CN116964047A (zh) | 2023-10-27 |
| CA3195293A1 (en) | 2022-04-28 |
| KR20230110509A (ko) | 2023-07-24 |
| AU2021366303A1 (en) | 2023-06-22 |
| US20230382905A1 (en) | 2023-11-30 |
| JP2023546225A (ja) | 2023-11-01 |
| EP4232154A1 (en) | 2023-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021012903A (es) | Moduladores de la via de respuesta integrada al estres. | |
| MX2021012904A (es) | Moduladores de la via de respuesta al estres integrada. | |
| MX2022009243A (es) | Moduladores de la via de respuesta integrada al estres. | |
| CR20200553A (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
| PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
| HK1062677A1 (en) | 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| BRPI0314308B8 (pt) | antagonistas de opióide, seus usos, e composição farmacêutica | |
| CR20220371A (es) | Agonistas heterocíclicos de glp-1 | |
| SE0202462D0 (sv) | Novel use | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
| MX2021010106A (es) | Inhibidores de la via de respuesta al estres integrada. | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| MX2023007853A (es) | Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo. | |
| MX2022011143A (es) | Moduladores de la via de respuesta integrada al estres. | |
| PH12020550168A1 (en) | Griseofulvin compound and pharmaceutical use thereof | |
| CR20220299A (es) | Derivados de becimidazol | |
| CR20230143A (es) | Degradadores de moléculas pequeñas de piperidinilo de helios y procedimientos de uso | |
| PH12021551035A1 (en) | Pyrazoles as modulators of hemoglobin | |
| MX2023009285A (es) | Compuestos novedosos. | |
| MX2022011697A (es) | Inhibidores de ciclofilina y usos de los mismos. | |
| MX2023004623A (es) | Moduladores de la via integrada de respuesta al estres. | |
| MX2023004626A (es) | Moduladores de la via de respuesta integrada al estres. | |
| MX2023004677A (es) | Moduladores de la via de respuesta integrada al estres. | |
| AU2021242808A8 (en) | Solid dispersions of amorphous 3, 4-diphenyl-4, 5-dihydro- 1H-pyrazole derivatives, compositions comprising them and uses thereof as cannabinoid CB1 receptor inhibitors |